Therapeutic potential of trazodone in trigeminal neuralgia based on inflammation and oxidative stress: an in vitro experimental study.

IF 1.9 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral & Facial Pain and Headache Pub Date : 2024-06-01 Epub Date: 2024-06-12 DOI:10.22514/jofph.2024.020

Jun Yang, Junling Huang, Zhimin Pan, Xiao Wang

{"title":"Therapeutic potential of trazodone in trigeminal neuralgia based on inflammation and oxidative stress: an in vitro experimental study.","authors":"Jun Yang, Junling Huang, Zhimin Pan, Xiao Wang","doi":"10.22514/jofph.2024.020","DOIUrl":null,"url":null,"abstract":"Trigeminal neuralgia (TN) is a debilitating condition affecting the patients' life quality. New therapeutic approaches and novel drugs are required to treat TN. Trazodone being a serotonin antagonist and reuptake inhibitor (SARI) provides neuroprotection, however its role and underlying mechanism in TN in vitro or in vivo are not clear. This study was aimed to investigate the trazodone impact on glial BV-2 cells regarding TN. It was found that trazodone inhibited the BV-2 cells growth and suppressed the inflammation and oxidative stress in Lipopolysaccharide (LPS)-treated BV-2 cells. Trazodone treatment specifically decreased the levels of Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-1 beta (IL-1β) (p < 0.05), and Reactive Oxygen Species (ROS) (p < 0.01). Moreover, trazodone suppressed the Mitogen-Activated Protein Kinase (MAPK) pathway in LPS-treated BV-2 cells. These outcomes demonstrate that trazodone suppressed glial cell hyperproliferation, inflammation, and oxidative stress through MAPK pathway activation.","PeriodicalId":48800,"journal":{"name":"Journal of Oral & Facial Pain and Headache","volume":"38 2","pages":"119-125"},"PeriodicalIF":1.9000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral & Facial Pain and Headache","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.22514/jofph.2024.020","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Trigeminal neuralgia (TN) is a debilitating condition affecting the patients' life quality. New therapeutic approaches and novel drugs are required to treat TN. Trazodone being a serotonin antagonist and reuptake inhibitor (SARI) provides neuroprotection, however its role and underlying mechanism in TN in vitro or in vivo are not clear. This study was aimed to investigate the trazodone impact on glial BV-2 cells regarding TN. It was found that trazodone inhibited the BV-2 cells growth and suppressed the inflammation and oxidative stress in Lipopolysaccharide (LPS)-treated BV-2 cells. Trazodone treatment specifically decreased the levels of Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-1 beta (IL-1β) (p < 0.05), and Reactive Oxygen Species (ROS) (p < 0.01). Moreover, trazodone suppressed the Mitogen-Activated Protein Kinase (MAPK) pathway in LPS-treated BV-2 cells. These outcomes demonstrate that trazodone suppressed glial cell hyperproliferation, inflammation, and oxidative stress through MAPK pathway activation.

查看原文本刊更多论文

曲唑酮治疗三叉神经痛基于炎症和氧化应激的潜力：一项体外实验研究。

三叉神经痛是一种影响患者生活质量的衰弱性疾病。治疗TN需要新的治疗方法和新药。曲唑酮作为5 -羟色胺拮抗剂和再摄取抑制剂（SARI）具有神经保护作用，但其在体外和体内对TN的作用和机制尚不清楚。本研究旨在探讨曲唑酮对神经胶质BV-2细胞TN的影响，发现曲唑酮能抑制BV-2细胞生长，抑制脂多糖（LPS）处理的BV-2细胞的炎症和氧化应激。曲唑酮治疗显著降低肿瘤坏死因子-α (TNF-α)、白细胞介素-6 （IL-6）、白细胞介素-1β (IL-1β)水平（p < 0.05）和活性氧（ROS）水平（p < 0.01）。此外，曲唑酮在lps处理的BV-2细胞中抑制丝裂原活化蛋白激酶（MAPK）通路。这些结果表明曲唑酮通过激活MAPK通路抑制神经胶质细胞增生、炎症和氧化应激。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oral & Facial Pain and Headache DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

5.10

自引率

4.00%

发文量

期刊介绍： Founded upon sound scientific principles, this journal continues to make important contributions that strongly influence the work of dental and medical professionals involved in treating oral and facial pain, including temporomandibular disorders, and headache. In addition to providing timely scientific research and clinical articles, the journal presents diagnostic techniques and treatment therapies for oral and facial pain, headache, mandibular dysfunction, and occlusion and covers pharmacology, physical therapy, surgery, and other pain-management methods.